EPT, or N-ethyl-N-propyltryptamine, is a synthetic tryptamine with one ethyl and one propyl group attached to the terminal nitrogen. It is an unsymmetrical analogue of DET and DPT and has appeared in forensic seizures in Japan and Europe. Its pharmacology has received little direct study, but a 2024 paper provided a detailed account of its metabolism in human liver microsomes and proposed markers for forensic identification.
Chemistry and identification
EPT is N-ethyl-N-propyl-2-(1H-indol-3-yl)ethanamine. The indole ring is unsubstituted, while the terminal nitrogen carries two different alkyl groups. This distinguishes it from DET, which has two ethyl groups, and DPT, which has two propyl groups.
The compound was identified in seized material in Japan between 2017 and 2019 and in Europe in 2018 and 2019. The 2024 study noted that pharmacological information for EPT and related analogues remained limited despite their appearance on the illicit market (Bergh and colleagues, 2024).
Pharmacology
There is no well-established receptor-binding or functional profile for EPT. Its tryptamine structure makes serotonergic activity a reasonable subject for investigation, but the available evidence does not establish its potency at 5-HT2A or other receptors. Data for 4-OH-EPT and 5-MeO-EPT should not be assigned to the unsubstituted compound.
Metabolism
The 2024 study incubated EPT with pooled human liver microsomes and identified six to seven of its more abundant metabolites. The proposed pathways included N-dealkylation, N-oxide formation, hydroxylation of the alkyl side chains and hydroxylation of the indole ring. Some of the observed metabolites were consistent with products reported previously in rat urine and human liver S9 experiments.
The study also found that 4-OH-EPT can arise as a metabolite of EPT. This creates an analytical challenge: detecting 4-OH-EPT in a biological sample does not, by itself, establish whether the person was exposed to EPT or to 4-OH-EPT directly. The researchers proposed additional metabolite markers that may help distinguish the two (Bergh and colleagues, Drug Testing and Analysis, 2024).
Reported effects and clinical evidence
Reliable human information is too limited to establish a characteristic EPT experience. The 2024 paper focused on metabolism and forensic detection, not controlled human pharmacology. Reports concerning DET, DPT or 4-substituted tryptamines cannot be treated as direct descriptions of EPT.
Toxicology and research limitations
No well-characterised clinical case series or controlled human study has established EPT’s acute toxic range, dependence potential or long-term effects. The metabolism research improves forensic identification, without fully establishing its pharmacological activity or clinical risks.
Related tryptamines
EPT is related to DET, DPT, 4-HO-EPT and 5-MeO-EPT. Its mixed ethyl-propyl nitrogen substitution distinguishes it from the symmetrical dialkyl analogues.
